Additionally, we showed that genetic and pharmacologic inhibition of CcO activity suppresses tumor growth and depletes GSCs in gliomas, providing a strategic opportunity to improve therapeutic outcomes in patients with GBM [12, 17, 50]. This evidence concerns the gene RYR1 and glioma.